Introduction {#sec1}
============

Tetanus is a non-communicable vaccine-preventable disease caused by the bacterium *Clostridium tetani (C. tetani)*. The disease cannot be eradicated because C. tetani spores exist in the environment \[[@cit0001]\]. Although tetanus can occur in all age-groups, neonates and women with recent pregnancies are most at risk, particularly when childbirths (or terminations of pregnancies) take place under unhygienic conditions \[[@cit0002]\]. Neonatal tetanus (NT) occurs during the first 28 days of life and maternal tetanus occurs during or within the first 6 weeks after pregnancy. Case-fatality rates from tetanus in resource-limited settings can be up to 100%, though with adequate medical care rates can be reduced to 10-20% \[[@cit0003]\].

Tetanus toxoid containing vaccine (TTCV) is one of the most effective, safe, heat-stable, and inexpensive vaccines ever developed \[[@cit0004]\]. TTCV can be given safely during pregnancy to protect both mothers and newborns \[[@cit0005]\]. Vaccines containing tetanus for infants and pregnant women have been part of the WHO Expanded Program on Immunizations since its inception. WHO recommends a 6 dose schedule of TTCV including 3 doses in infancy and 3 booster doses, 1 each during the second year of life, childhood (4--7 years), and adolescence (9--15 years), to provide long-term protection against tetanus in all ages \[[@cit0003]\]. For previously non-immunized adolescents and adults, a total of 5 TTCV doses are recommended \[[@cit0003]\]. In countries where maternal and neonatal tetanus (MNT) is still a problem, pregnant women whose tetanus vaccination history is unknown or inadequate are recommended to receive 2 TTCV doses during their first pregnancy, with the first dose provided at first contact with health services and the second dose provided at least 4 weeks later and at least 2 weeks before delivery \[[@cit0003]\]. The third dose can be given at least 6 months after the second, and 2 boosters are provided during subsequent pregnancies or at least 1 year later. This schedule has been shown to reduce neonatal mortality from tetanus by 94% \[[@cit0005]\].

In industrialized countries, MNT was generally eliminated before vaccine introduction through clean birth practices \[[@cit0006]\]. Deliveries assisted by skilled birth attendants (SBA), who can ensure clean delivery practices and education on hygienic umbilical cord practices, has been shown to be an effective intervention to prevent MNT and to reduce neonatal mortality due to tetanus by 50--70% \[[@cit0006]-[@cit0009]\].

In 1988, NT was estimated to cause over 787,000 deaths per year \[[@cit0010]\]. To address the global burden of NT, in 1989, The World Health Assembly called for the elimination of NT by 1995, defined as an incidence of \<1 NT case per 1,000 live births in every district annually \[[@cit0011]\]. Maternal tetanus elimination was added in 1999, and the goal was relaunched through a partnership with World Health Organization (WHO), United Nations Children's Fund (UNICEF), and United Nations Population Fund (UNFPA) as the Maternal and Neonatal Tetanus Elimination (MNTE) Initiative, focusing on 59 priority countries (including the addition of Timor Leste and South Sudan) that had not yet achieved elimination as of 2000 \[[@cit0007], [@cit0012]\]. The strategies recommended by the UN agency partnership to achieve MNTE are 1) routine immunization of women during pregnancy with TTCV, 2) immunization of all women of reproductive age (WRA) living in high risk areas with 3 doses of TTCV, 3) delivery by SBA to ensure clean delivery practices, and 4) surveillance for NT cases \[[@cit0007]\]. High-risk districts for MNT are defined as those reporting clean delivery coverage of \< 70% and coverage with at least 2 TTCV doses \<80% during the past 5 years among pregnant women or WRA \[[@cit0012]\]. All WRA living in high-risk areas are provided 3 doses of TTCV irrespective of their previous vaccination status, through appropriately spaced supplementary immunization activity (SIA) rounds \[[@cit0012]\]. As a result of MNTE efforts, the estimated number of NT deaths has been reduced by 94% (49,000 estimated deaths) in 2013, compared to 1988 \[[@cit0013]\]. However, the target date for MNTE has been repeatedly missed and extended; the most recent target date was 2015 \[[@cit0007]\]. As of October 2016, 41 (69%) of the 59 priority countries identified have achieved MNTE \[[@cit0014]\].

Beyond MNTE, a goal of tetanus vaccination is to prevent tetanus in all ages \[[@cit0003]\].The Global Vaccine Action Plan (GVAP) set a target of 90% coverage with three doses of diphtheria, tetanus, and pertussis containing vaccine (DTP3/Penta) among children aged \<12 months nationally, and 80% in every district by 2015 \[[@cit0015]\]. GVAP objectives also emphasize equitable provision of vaccines to underserved areas and marginalized groups, as well as introducing strategies to provide vaccinations to all ages ("life course approach"). High vaccination coverage and provision of tetanus booster doses throughout the lifespan would raise population immunity and sustain achievements of the MNTE Initiative.

The World Health Organization (WHO) African Region (AFR) consists of 47 countries in Sub-Saharan Africa that carry a substantial burden of the remaining MNT cases. In this paper, we describe the current status of progress towards MNTE in AFR, discuss the challenges and barriers to reaching elimination, and make recommendations for reaching and maintaining elimination in the region.

Methods {#sec2}
=======

For each country in AFR, we reviewed national vaccination schedules, vaccination coverage estimates and reported NT cases from the WHO-UNICEF joint reporting form available on the WHO website \[[@cit0016]-[@cit0021]\]. WHO-UNICEF coverage estimates were reviewed to determine coverage of the third dose of Diphtheria Tetanus and Pertussis vaccine (DTP3)/Pentavalent vaccine (Penta 3) among children aged \<12 months and the proportion of births in a given year that can be considered as having been protected against tetanus (protected at birth, PAB) as a result of maternal immunization \[[@cit0019], [@cit0020]\]. WHO-UNICEF estimates of PAB were calculated on the basis of mathematical modeling \[[@cit0022]\], whereas PAB is usually defined as having received 2 tetanus toxoid (TT) doses during the last birth, ≥2 TT doses with the last dose ≥ 3 years prior to the last birth, ≥3 doses with the last dose ≤ 5 years prior, ≥4 doses with the last dose ≤10 years prior, or ≥ 5 prior doses \[[@cit0023]\]. Official country administrative coverage figures reported to WHO-UNICEF were reviewed for the proportion of women who have received their second or subsequent dose of TTCV during pregnancy (TT2+) \[[@cit0021]\]. Administrative TT2+ coverage is calculated by dividing the number of pregnant women who received the second or subsequent dose of TT by the estimated number of live births for the year \[[@cit0024]\]. 2005, 2010, and 2011-2015 averages forDTP3/Penta3, TT2+, and PAB coverage were calculated for countries yet to achieve MNTE and those that have achieved MNTE using the formula: (sum of (coverage x target population)) / sum of target populations). NT incidence rates were calculated for each country based on the number of reported cases divided by the number of births. Population denominators are from the United Nations Population Division \[[@cit0025]\].

The number of WRA (generally 15--49 years of age) targeted and reached with TT2+ by SIAs for each country yet to achieve elimination were reviewed from the WHO data on MNTE SIAs \[[@cit0026]\]. The proportion of deliveries attended by a SBA as reported to UNICEF were reviewed for each country in the region \[[@cit0027]\]. We searched PubMed and the WHO website for relevant articles and reports relating to MNTE globally or within AFR published up to September 1, 2016 \[[@cit0028]\]. Additionally, we reviewed presentations and reports from the Strategic Advisory Group of Experts Working Group on Maternal and Neonatal Tetanus Elimination and Broader Tetanus Prevention \[[@cit0029]\].

Current status of knowledge {#sec3}
===========================

Current status of MNTE Initiative in AFR {#sec3.1}
----------------------------------------

When the MNTE Initiative was re-launched in 1999, only 9 (19%) of the 47 countries in the WHO African Region had eliminated MNT (Algeria, Botswana, Cabo Verde, The Gambia, Lesotho, Mauritius, Sao Tome and Principe, Seychelles, and Swaziland). As of November 2016, 28 additional countries in the region have eliminated MNT, for a total of 37 (79%) countries, leaving 10 countries yet to achieve MNTE (Angola, Central African Republic (CAR), Chad, Democratic Republic of the Congo (DRC), Ethiopia (Somali Region only), Guinea, Kenya, Mali, Nigeria, South Sudan) ([Figure 1](#f0001){ref-type="fig"}). In those 10 countries, the risk of MNT is mainly limited to a few high-risk districts except in countries that are challenged with civil unrest and insecurity (CAR, DRC, Mali, and Nigeria).

![Maternal Neonatal Tetanus Elimination Status- WHO African Region, 2016](PAMJ-SUPP-27-3-24-g001){#f0001}

Tetanus vaccination coverage {#sec3.2}
----------------------------

Immunization programs of all 47 AFR countries recommend three TTCV doses for infants and five appropriately spaced doses for pregnant women and/or WRA, where appropriate \[[@cit0016]\]. Of the 37 AFR countries that have achieved MNTE, five (14%) include the three WHO-recommended TTCV booster doses for children older than 1 year of age in their immunization schedules (Algeria, Botswana, Mauritius, Seychelles, and South Africa); none of the 10 countries yet to achieve MNTE provide the three WHO-recommended tetanus booster doses in their vaccination schedule \[[@cit0016]\].

The regional average for DTP3/Penta3 coverage has increased from 52% in 2000 to 76% in 2015 overall, though coverage in several countries has not improved during this time period \[[@cit0019], [@cit0030]\]. In 2015, DTP3/Penta3 coverage among countries that had achieved MNTE was 84% compared with 68% among countries that had not yet achieved MNTE ([Figure 2](#f0002){ref-type="fig"}). Of the AFR countries that have achieved elimination, 16 (43%) had ≥90% DTP3/Penta3 coverage in 2015 ([Table 1](#t0001){ref-type="table"}). Of the 10 countries that have not achieved MNTE, Kenya is the only country that has ever reached ≥90% DTP3/Penta3 coverage though not in every year since 2010 ([Table 2](#t0002){ref-type="table"}). Ebola-affected countries (Guinea, Liberia, and Sierra Leone) experienced decreases in DTP3/Penta3 coverage rates during and following the outbreak in 2014 and 2015. Over the same time period, Angola and South Sudan had decreases in DTP3/Penta3 coverage, likely due to insecurity. Notably, DTP3/Penta3 coverage has been consistently low (\<65%) in Equatorial Guinea which achieved elimination in 2016; such coverage may prove a challenge for maintaining elimination.

###### 

WHO-UNICEF Coverage Estimates for the third dose of Diphtheria, Tetanus, and Pertussis Vaccine (DTP3/Penta3) among children aged \<12 Months in countries that have achieved Maternal Neonatal Tetanus Elimination --- WHO Africa Region 2000, 2005, and 2010-2015[^a^](#tf1-1){ref-type="fn"}

  Country                                             2000   2005   2010   2011   2012   2013   2014   2015
  --------------------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------
  Algeria[^b^](#tf1-2){ref-type="fn"}                 86     88     95     95     95     95     95     95
  Benin                                               78     70     76     75     81     74     75     79
  Botswana[^b^](#tf1-2){ref-type="fn"}                97     96     95     95     95     95     95     95
  Burkina Faso                                        45     82     91     91     90     88     91     91
  Burundi                                             80     87     96     96     96     96     95     94
  Cabo Verde[^b^](#tf1-2){ref-type="fn"}              90     95     99     90     94     93     95     93
  Cameroon                                            62     80     84     82     85     89     87     84
  Comoros                                             70     68     74     83     86     83     80     80
  Congo                                               33     62     74     80     79     85     90     80
  Cote d\'Ivoire                                      65     76     85     62     82     80     76     83
  Equatorial Guinea                                   34     39     44     41     24     3      20     16
  Eritrea                                             81     96     90     96     94     94     94     95
  Gabon                                               45     45     67     75     82     79     70     80
  Gambia[^b^](#tf1-2){ref-type="fn"}                  80     95     97     96     98     97     96     97
  Ghana                                               88     84     94     91     92     90     98     88
  Guinea-Bissau                                       49     68     80     80     80     80     80     80
  Lesotho[^b^](#tf1-2){ref-type="fn"}                 83     89     93     96     95     93     93     93
  Liberia                                             46     60     70     77     80     76     50     52
  Madagascar                                          57     85     70     73     70     74     73     69
  Malawi                                              75     93     93     97     96     89     91     88
  Mauritania                                          51     71     64     75     80     80     84     73
  Mauritius[^b^](#tf1-2){ref-type="fn"}               88     97     99     98     98     98     97     97
  Mozambique                                          70     80     74     76     76     78     79     80
  Namibia                                             79     86     83     82     84     89     88     92
  Niger                                               34     45     70     75     71     67     68     65
  Rwanda                                              90     95     97     97     98     98     98     98
  Sao Tome and Principe[^b^](#tf1-2){ref-type="fn"}   82     97     98     96     96     97     95     96
  Senegal                                             52     84     89     92     91     92     89     89
  Seychelles[^b^](#tf1-2){ref-type="fn"}              98     99     99     99     98     98     99     97
  Sierra Leone                                        44     65     86     89     91     92     83     86
  South Africa                                        73     72     66     72     68     65     70     69
  Swaziland[^b^](#tf1-2){ref-type="fn"}               84     86     89     91     95     98     98     90
  Togo                                                64     82     83     85     84     84     87     88
  Uganda                                              52     64     80     82     78     78     78     78
  United Republic of Tanzania                         79     90     91     90     92     91     97     98
  Zambia                                              85     82     83     81     78     79     86     90
  Zimbabwe                                            78     68     89     93     95     95     91     87
  Average[^c^](#tf1-3){ref-type="fn"}                 68     78     83     84     84     84     85     84

WHO-UNICEF estimates of DTP3 coverage. Last updated July 15, 2016. Available from <http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragedtp3.html> Accessed September 18, 2016.

Eliminated Maternal and Neonatal Tetanus Prior to 2000.

Average calculated as \[sum of (coverage x surviving infants)\] / sum of surviving infants. Denominator of total surviving infants to age 1 available from United Nations, Department of Economic and Social Affairs, Population Division (2015). World Population Prospects: The 2015 Revision, DVD Edition. Available from <https://esa.un.org/unpd/wpp/Download/Standard/Population/> Accessed on September 18, 2016

###### 

WHO-UNICEF coverage estimates for the third Dose of Diphtheria, Tetanus, and Pertussis Vaccine (DTP3/Penta3) among children Aged \<12 months in countries that have not achieved Maternal Neonatal Tetanus Elimination --- WHO Africa Region 2000, 2005, and 2010-2015[^a^](#tf2-1){ref-type="fn"}

  Country                               2000   2005   2010   2011   2012   2013   2014   2015
  ------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------
  Angola                                28     38     77     71     75     77     64     64
  Central African Republic              37     54     45     47     47     23     47     47
  Chad                                  36     25     39     33     45     48     46     55
  DR of Congo                           40     60     60     74     75     74     80     81
  Ethiopia                              30     44     61     65     69     72     77     86
  Guinea                                46     59     64     63     62     63     51     51
  Kenya                                 82     76     90     96     94     87     92     89
  Mali                                  43     77     73     66     68     71     77     68
  Nigeria                               29     36     54     48     42     46     49     56
  South Sudan                           NA     NA     NA     61     59     45     39     31
  Average[^b^](#tf2-2){ref-type="fn"}   36     46     60     62     61     62     65     68

WHO-UNICEF estimates of DTP3 coverage. Last updated July 15, 2016. Available from <http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragedtp3.html> Accessed September 18, 2016.

Average calculated as \[sum of (coverage x surviving infants)\] / sum of surviving infants. Denominator of total surviving infants to age 1 available from United Nations, Department of Economic and Social Affairs, Population Division (2015). World Population Prospects: The 2015 Revision, DVD Edition. Available from <https://esa.un.org/unpd/wpp/Download/Standard/Population/> Accessed on September 18, 2016.

![Average tetanus vaccination coverage of WHO African region countries by maternal and neonatal tetanus elimination status during 2000, 2005, 2010 and 2015](PAMJ-SUPP-27-3-24-g002){#f0002}

Both TT2+ and PAB coverage are estimates of tetanus immunity among pregnant women. The percentage of pregnant women covered with TT2+ among all countries in the AFR region increased from 44% in 2000 to 69% in 2015; PAB increased from 62% to 77% during the same time period \[[@cit0030]\]. In countries that have achieved MNTE, the average PAB and TT2+ coverage for 2015 was 86% and 64%, respectively ([Figure 2](#f0002){ref-type="fig"}), with ≥ 80% TT2+ or PAB coverage in all but Equatorial Guinea, Madagascar, and Zimbabwe ([Table 3](#t0003){ref-type="table"}). Of the AFR countries that have not yet achieved MNTE, the average PAB and TT2+ coverage in 2015 was 69% and 64%, respectively ([Figure 2](#f0002){ref-type="fig"}); among these countries, ≥80% TT2+ or PAB coverage was achieved in Chad, DRC, Ethiopia, Guinea, Kenya, and Mali ([Table 4](#t0004){ref-type="table"}). Guinea and Liberia, which were affected by the 2014 Ebola outbreak, had lower TT2+ coverage in 2014 and 2015 relative to other years, but PAB remained stable. However, Sierra Leone, also affected by the Ebola outbreak, did not have a drop in TT2+ or PAB coverage.TT2+ coverage can underestimate true protection from tetanus, especially in countries with well-established vaccination programs (e.g. Botswana, Cabo Verde, and Comoros), because it excludes women unvaccinated during pregnancy but already protected through previous vaccination or who received one dose in pregnancy and had undocumented previous doses ([Table 3](#t0003){ref-type="table"}) \[[@cit0023], [@cit0024]\].

###### 

Tetanus coverage[^a^](#tf3-1){ref-type="fn"},[^b^](#tf3-2){ref-type="fn"} among pregnant women in countries that have not achieved Maternal and Neonatal Tetanus Elimination --- WHO African Region, 2000, 2005, and 2010-2015

                                           2000   2005   2010   2011   2012   2013   2014   2015                                      
  ---------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ---- ---- ---- ---- ---- ---- ---- ----
  Alqeria[^c^](#tf3-3){ref-type="fn"}      64     ΝΑ     69     ΝΑ     90     NA     90     NA     90   NA   90   NA   92   NA   92   NA
  Benin                                    87     81     95     65     92     63     92     77     93   82   93   69   93   69   85   77
  Botswana[^c^](#tf3-3){ref-type="fn"}     80     45     83     72     92     64     92     81     92   79   92   70   92   52   92   53
  Burkina Faso                             57     NA     72     71     85     82     88     82     88   86   88   71   89   91   92   91
  Burundi                                  51     28     65     33     94     94     80     99     85   88   85   96   85   80   85   90
  Cabo Verde[^c^](#tf3-3){ref-type="fn"}   60     45     70     55     92     NA     92     NA     92   64   92   63   92   82   92   64
  Cameroon                                 54     40     76     60     91     74     75     69     85   65   85   68   85   64   85   62
  Comoros                                  57     40     91     80     85     38     85     65     85   61   85   NA   85   51   85   55
  Congo                                    67     39     75     62     83     92     83     92     83   85   83   85   85   90   85   85
  Cote d\'Ivoire                           76     78     75     34     82     62     82     59     82   84   82   81   82   77   85   80
  Equatorial Guinea                        61     30     59     25     75     54     75     64     75   30   75   31   70   36   70   23
  Eritrea                                  80     25     84     70     93     35     93     35     94   35   94   94   94   35   94   65
  Gabon                                    39     16     58     34     75     51     75     57     75   59   85   57   85   54   85   59
  Gambia[^c^](#tf3-3){ref-type="fn"}       92     90     89     71     91     88     91     61     92   71   82   78   92   60   92   82
  Ghana                                    69     73     83     71     86     80     88     76     88   72   88   71   88   42   88   78
  Guinea-Bissau                            49     NA     65     40     78     70     80     32     80   45   80   38   80   70   80   83
  Lesotho[^c^](#tf3-3){ref-type="fn"}      73     NA     79     NA     83     80     83     57     83   36   83   39   83   47   83   68
  Liberia                                  51     25     60     72     91     63     91     74     91   74   91   76   89   68   89   63
  Madagascar                               58     40     66     47     76     58     78     62     78   59   78   63   78   53   78   47
  Malawi                                   84     61     86     63     87     89     87     79     89   71   89   65   89   90   89   54
  Mauritania                               44     NA     59     34     87     30     80     29     80   40   80   40   80   42   80   37
  Mauritius[^c^](#tf3-3){ref-type="fn"}    79     76     86     88     95     96     95     95     95   95   95   85   95   85   95   83
  Mozambique                               75     61     77     62     83     69     83     70     83   70   83   64   83   66   83   80
  Namibia                                  74     60     80     99     83     75     83     64     83   67   83   72   85   71   85   70
  Niger                                    63     31     69     54     84     85     84     93     84   83   81   89   81   90   81   73
  Rwanda                                   81     NA     79     54     85     58     85     62     85   76   85   78   90   92   90   99
  Sao Tome and Principes                   NA     75     99     99     99     87     99     90     99   92   99   90   99   91   99   92
  Senegal                                  62     45     80     67     88     60     88     NA     91   70   91   88   91   84   91   84
  Seychelles[^c^](#tf3-3){ref-type="fn"}   NA     NA     NA     99     NA     99     NA     99     NA   NA   NA   99   NA   97   NA   99
  Sierra Leone                             53     20     83     66     85     90     85     90     87   60   87   81   85   90   85   92
  South Africa                             68     65     59     43     77     NA     77     51     77   63   77   NA   80   NA   80   NA
  Swaziland[^c^](#tf3-3){ref-type="fn"}    80     94     82     83     86     90     86     79     86   53   86   72   88   72   88   57
  Togo                                     63     47     81     70     81     85     81     86     81   78   77   78   81   80   81   78
  Uganda                                   70     42     85     55     85     53     85     49     85   49   85   56   85   56   85   58
  United Republic of Tanzania              79     77     81     81     83     73     88     76     88   79   88   79   88   93   90   94
  Zambia                                   78     61     91     83     90     72     81     74     81   71   81   74   85   74   85   75
  Zimbabwe                                 76     60     77     80     76     60     66     80     66   85   66   75   75   58   75   NA
  Averaqe[^d^](#tf3-4){ref-type="fn"}      69     49     76     58     85     61     84     64     85   67   84   61   85   64   86   64

PAB=Protection at birth. PAB is usually defined as receiving 2 tetanus toxoid containing vaccine (TTCV) doses during the last birth, \>2 TTCV doses with the last dose \<3 years prior to the last birth, \>3 doses with the last dose \<5 years prior, \>4 doses with the last dose \<10 years prior, or \>5 prior doses. WHO-UNICEF annual estimates of PAB were calculated on the basis of mathematical modeling WHO-UNICEF estimates of PAB coverage. Last updated July 15, 2016. Available from <http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragepab.html> Accessed December 18, 2016.

TT2+ = Proportion of women who have received their second or subsequent dose of TTCV during pregnancy. Reported estimates of TT2+ coverage. Last updated November 18, 2016. Available from <http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tscoveragett2plus.html> Accessed December 18, 2016.

Eliminated Maternal and Neonatal Tetanus Prior to 2000.

Average calculated as \[sum of (coverage χ births)\] / sum of births. Denominator of births available from United Nations, Department of Economic and Social Affairs, Population Division (2015). World Population Prospects: The 2015 Revision, DVD Edition. Available from <https://esa.un.org/unpd/wpp/Download/Standard/Population/Accessed> on September 18, 2016.

###### 

Tetanus coverage[^a^](#tf4-1){ref-type="fn"},[^b^](#tf4-2){ref-type="fn"} among pregnant women in countries that have not achieved Maternal and Neonatal Tetanus Elimination --- WHO African Region, 2000, 2005, and 2010-2015

                                        2000   2005   2010   2011   2012   2013   2014   2015                                      
  ------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ---- ---- ---- ---- ---- ---- ---- ----
  Angola                                60     NA     75     53     75     87     70     79     72   78   75   83   78   76   78   71
  Central African                       36     20     48     34     86     50     80     81     66   76   66   33   60   53   60   52
  Republic                                                                                                                         
  Chad                                  39     12     61     NA     60     77     60     60     43   70   50   78   60   83   75   96
  DR of Congo                           45     25     67     66     77     85     70     84     70   86   75   85   82   88   82   91
  Ethiopia                              54     32     80     45     88     NA     88     1      68   66   72   NA   80   NA   80   92
  Guinea                                79     43     90     75     90     70     80     80     80   86   80   93   80   62   80   54
  Kenya                                 68     51     73     72     78     72     73     76     73   NA   73   77   76   55   80   55
  Mali                                  50     62     86     63     85     59     89     60     89   66   85   95   85   86   85   63
  Nigeria                               57     NA     62     52     69     39     60     44     60   56   60   39   55   44   55   40
  South Sudan                           NA     NA     NA     NA     NA     NA     NA     61     NA   50   NA   41   NA   45   NA   28
  Average[^c^](#tf4-3){ref-type="fn"}   54     19     68     53     74     48     69     51     65   61   66   51   68   50   69   64

PAB=Protection at birth. PAB is usually defined as receiving 2 tetanus toxoid containing vaccine (TTCV) doses during the last birth, \>2 TTCV doses with the last dose \<3 years prior to the last birth, \>3 doses with the last dose \<5 years prior, \>4 doses with the last dose \<10 years prior, or \>5 prior doses. WHO-UNICEF annual estimates of PAB were calculated on the basis of mathematical modeling WHO-UNICEF estimates of PAB coverage. Last updated July 15, 2016. Available from <http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragepab.html> Accessed December 18, 2016.

TT2+ = Proportion of women who have received their second or subsequent dose of TTCV during pregnancy. Reported estimates of TT2+ coverage. Last updated November 18, 2016. Available from <http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tscoveragett2plus.html> Accessed December 18, 2016.

Average calculated as \[sum of (coverage χ births)\] / sum of births. Denominator of births available from United Nations, Department of Economic and Social Affairs, Population Division (2015). World Population Prospects: The 2015 Revision, DVD Edition. Available from <https://esa.un.org/unpd/wpp/Download/Standard/Population/> Accessed on September 18, 2016.

During 1999 to the end of 2016, over 79 million WRA were vaccinated with at least 2 TTCV doses during SIAs in AFR countries, but by the end of 2016 about 5.5 million WRA in AFR countries still need to be reached. Only a limited number of districts are assessed as high-risk in the 10 countries remaining to achieve MNTE (e.g., in DRC only 11 of the 514 health zones are high-risk). The total number of TTSIA phases completed as of April 2016 and number of TT2+ doses provided through SIAs are reported for countries yet to achieve MNTE in [Table 5](#t0005){ref-type="table"}. Most of the required funds are available to support Angola, Chad, DRC, Ethiopia, Guinea, Kenya, and South Sudan to complete all their planned and final TTCV SIAs; these countries are on course to achieve elimination by 2018 \[[@cit0031]\]. However, most of the funding for TTCV SIAs in CAR, Mali, and Nigeria is still lacking \[[@cit0031]\].

###### 

Number of TT supplementary immunization activities and years conducted, number of TT2+ doses provided through SIAs, current skilled birth attendant coverage, and reported neonatal tetanus cases and incidence in countries that have not achieved Maternal and Neonatal Tetanus Elimination - African Region

  Country       No. of TT SIA phases[^a^](#tf5-1){ref-type="fn"} (years conducted)   No. of TT2+ doses providedthrough SIAs[^b^](#tf5-2){ref-type="fn"}   No. of WRA (aged 15-49 years) in 2015[^c^](#tf5-3){ref-type="fn"}   \% births attended by SBA[^d^](#tf5-4){ref-type="fn"}(year measured)   No. ofreported NT cases in 2015[^e^](#tf5-5){ref-type="fn"}   Reported incidence of NT cases in 2015 per 1,000 births[^f^](#tf5-6){ref-type="fn"},[^g^](#tf5-7){ref-type="fn"}
  ------------- -------------------------------------------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------
  Angola        4 Phases (2003-2014)                                                 7,097,552                                                            5,570,000                                                           47 (2007)                                                              36                                                            0.03
  CAR           1 phase (2008)                                                       804,984                                                              1,225,000                                                           54 (2010)                                                              96                                                            0.59
  Chad          5 phases (2000-2016)                                                 3,045,147                                                            3,091,000                                                           24 (2015)                                                              195                                                           0.31
  DRC           8 phases (2004-2014)                                                 10,293,095                                                           17,320,000                                                          80 (2014)                                                              330                                                           0.10
  Ethiopia      13 phases(19992016)                                                  12,786,464[^h^](#tf5-8){ref-type="fn"}                               24,103,000                                                          16 (2014)                                                              18                                                            0.01
  Guinea        4 phases(2003-2012)                                                  3,140,970                                                            2,932,000                                                           45 (2012)                                                              NA                                                            NA
  Kenya         6 phases(2002-2016)                                                  4,339,702                                                            11,175,000                                                          62 (2014)                                                              32                                                            0.02
  Mali          8 phases(2002-2014)                                                  3,802,724                                                            3,846,000                                                           56 (2006)                                                              8                                                             0.01
  Nigeria       4 phases(2009-2016)                                                  2,488,283                                                            41,363,000                                                          38 (2013)                                                              53                                                            0.01
  South Sudan   12 phases (20012016)                                                 3,226,433                                                            2,935,000                                                           19 (2010)                                                              0                                                             0

Abbreviations: CAR=Central African Republic; DRC=Democratic Republic of Congo; SIAs=supplemental immunization; SBA=skilled birth attendant; NA=not available; NT=neonatal tetanus

In most cases, phase refers to 3 rounds of SIAs in particular set of high-risk districts

Supplementary Immunization Activities MNTE. Last updated April 21, 2016. Available at <http://www.who.int/immunization/diseases/MNTE_initiative/en/index7.html> Accessed December 19, 2016. Women may be targeted and reached more than once through SIAs.

Population of females aged 15-49 years from United Nations, Department of Economic and Social Affairs, Population Division (2015). World Population Prospects: The 2015 Revision, DVD Edition. Available from <https://esa.un.org/unpd/wpp/Download/Standard/Population/> Accessed on December 18, 2016.

UNICEF global databases 2016 based on DHS, MICS and other nationally representative surveys. Last updated February, 2016. Available at <http://data.unicef.org/maternal-health/delivery-care.html> Accessed September 18, 2016.

Tetanus (neonatal) reported cases. Last updated December 1, 2016. Available at <http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tsincidencentetanus.html> Accessed December 18, 2016.

Denominator data of number of births Available from United Nations, Department of Economic and Social Affairs, Population Division (2015). World Population Prospects: The 2015 Revision, DVD Edition. Available from <https://esa.un.org/unpd/wpp/Download/Standard/Population/> Accessed on December 18, 2016.

Reported NT incidences are national and do not represent district level data used to determine elimination status (\<1 NT case per 1000 live births in every district annually). Underreporting of NT cases is common, with the efficiency of notification for NT cases globally estimated at less than 11% by Khan et al \[[@cit0002]\].

TT2+ doses are missing for phases 11 and 12 because round-wise coverage was reported instead of individual level coverage for receipt of multiple doses.

Clean delivery and cord care {#sec3.3}
----------------------------

In addition to vaccination, clean delivery and cord care are essential interventions to prevent and eliminate MNT. The proportion of births delivered by SBAs is a key indicator for monitoring progress towards MNTE. In AFR, the percentage of births attended by SBAs was 54% in 2013 \[[@cit0032]\]. Of countries that have achieved MNTE, 17 of 37 (46%) have \>70% SBA coverage, while 20 (54%) have \<70% SBA coverage; Eritrea (34% in 2010), Niger (40% in 2015), Madagascar (44% in 2013), Guinea-Bissau (45% in 2014), and United Republic of Tanzania (49% in 2014) have SBA coverage \<50% \[[@cit0027]\]. Four of these countries with \<50% SBA coverage have \>80% PAB coverage, while Madagascar has 78% PAB coverage. All countries that have not achieved MNTE have \<70% (range 19%-62%) SBA coverage in their last national survey except for DRC, which achieved 80% SBA coverage nationally in 2014 ([Table 5](#t0005){ref-type="table"}). Continued low PAB and SBA coverage could be a risk for sustaining MNTE.

Surveillance {#sec3.4}
------------

Sensitive NT surveillance is important for conducting epidemiologic analysis of cases, planning targeted interventions, and evaluating program effectiveness. WHO recommends routine monthly surveillance of NT, including zero reporting, active surveillance, and retrospective record review at major health facilities at least once a year to identify previously unreported NT cases \[[@cit0033]\]. During 2015, the number of NT cases reported from countries that have not achieved MNTE ranged from 0 in South Sudan to 330 in the DRC, with a respective reported national incidence of 0 to 0.59 NT cases per 1,000 live births ([Table 5](#t0005){ref-type="table"}).However, underreporting of NT surveillance is common, with the efficiency of notification for NT cases globally estimated at less than 11% \[[@cit0002]\]. Likely causes of NT underreporting include the general occurrence of NT cases in remote and underserved areas, NT deaths occurring in the community without being seen by a health worker, and lack of a robust system of active NT surveillance in most countries.

Serosurveys can help monitor progress towards achieving or maintaining MNTE, especially in countries or areas where TT2+ or PAB coverage may not be accurate. In Burundi in 1989, a national serosurvey among women giving birth in the previous year reported 73% PAB coverage and 67% seroprotection \[[@cit0034]\]. More recently, a national serosurvey in CAR in 1995 reported 74% PAB and 89% seroprotection among women giving birth in the past year \[[@cit0035]\]. In Cambodia in 2012, seroprotection was 88% for WRA overall, while parous women had 83% PAB and 97% seroprotection \[[@cit0023]\]. PAB coverage can be underestimated due to residual immunity from infant doses in some adult women, booster doses provided outside routine services, misclassification of PAB status due to poor availability of documentation, and recall bias \[[@cit0023]\]. Serosurveys can help estimate population immunity, which contributes to validation of MNTE, and identify areas at high risk for MNT \[[@cit0036]\]. Integration of tetanus testing in serosurveys for other antigens (e.g., rubella) using multiplex testing may reduce the cost and resources required \[[@cit0023]\].

Challenges and recommendations for AFR countries that have not yet achieved MNTE {#sec3.5}
--------------------------------------------------------------------------------

A number of challenges exist among the countries that have not yet achieved MNTE. In all the countries that have not yet achieved elimination, weak health systems affect their ability to effectively implement the four MNTE strategies. In most countries, sub-optimal routine immunization is evidenced by low rates of DTP3/Penta3 and TT2+/PAB coverage. The proportion of safe deliveries occurring in health facilities or at home with skilled birth attendants also remains low. Insecurity and unrest in CAR, Nigeria, Mali, and some areas of other countries result in WRAs living in high-risk areas being inaccessible. These countries also have challenges with funding the remaining TTCV SIAs needed to achieve MNTE. Vaccine controversy issues related to targeted vaccination of WRA have also occurred, resulting in varying extents of vaccine hesitancy. In Kenya, the national Conference of Catholic Bishops made public allegations that tetanus vaccine could cause sterility in women, which has delayed the country's timeline for MNTE \[[@cit0037]\]. Furthermore, AFR countries face competing priorities both within the EPI program, such as polio eradication (e.g., Nigeria) and measles elimination activities (i.e., throughout AFR), response campaigns to meningitis serogroup A and yellow fever outbreaks, and with other health programs (e.g., Ebola, HIV, TB, malaria).

Despite these challenges, MNTE is achievable in the remaining 10 AFR countries if there is strong national commitment, timely availability of resources, high quality micro plans, well implemented activities with monitoring and supervision, active community engagement, and adequate coordination with and implementation of maternal and child health services \[[@cit0031]\]. The methods to approach the MNTE strategies to reach elimination vary by country.

Efforts to strengthen the health care system of AFR countries yet to achieve MNTE could result in increased vaccination of pregnant women through routine services along with improving rates of clean deliveries. Eritrea, Rwanda, South Africa, and Zimbabwe were successful at eliminating MNT through efforts to strengthen the health system, without conducting any TTCV SIAs \[[@cit0031]\]. To achieve MNTE, Eritrea and Liberia promoted clean deliveries through additional training of traditional birth attendants \[[@cit0038], [@cit0039]\]. Liberia also encouraged facility births with distribution of free kits for mothers, including baby articles and bed nets \[[@cit0039]\]. Burundi constructed and staffed rural health facilities with trained health workers to provide free health care for mothers and children, in addition to conducting catch-up vaccination during mother and child health weeks \[[@cit0040]\]. Immunization programs should encourage using every opportunity to provide TTCV to women (e.g., child health days, outreach immunization sessions, periodic intensification of routine immunization, antenatal care visits, family planning visits) to improve coverage. Providing TTCV booster doses in the routine immunization schedule (e.g., in the second year of life with MCV2, or in school) can ensure women are protected, or need fewer booster doses to be protected, by the time they reach reproductive age. Mozambique provides TTCV to WRA during routine EPI sessions and also in secondary schools and workplaces; in addition, children of both sexes are provided TTCV in the first and second grade resulting in continued seroprotection of older children and adolescents \[[@cit0041], [@cit0042]\].

Many countries conduct multiple polio and measles SIAs, with many targeting hard-to-reach, inaccessible or previously inaccessible areas (i.e., conflict affected). Integrated campaigns that include TTCV could be an opportunity to reach WRA in high-risk areas. For countries with inaccessible areas or insecurity, innovative approaches such as use of TT-Uniject™ (a heat-stable prefilled injection device) could help reach these populations and improve TTCV coverage for WRA. An evaluation in Mali, where there are a limited number of health workers, showed that community-based volunteers could safely administer TT-Uniject™, communities were accepting of the practice, and previously inaccessible populations were reached \[[@cit0043]\]. Use of TT-Uniject™ during campaigns would allow unskilled vaccinators to provide vaccine, similar to polio SIAs.

India achieved MNTE in 2015 by employing a combination of approaches that may be applicable for some AFR countries. India faced similar challenges to the AFR region including a history of unsafe birth practices during home deliveries and suboptimal TTCV coverage \[[@cit0044]\]. Some of the approaches used in India to achieve MNTE included addition of TTCV booster doses to the childhood immunization schedule, immunization of pregnant women during antenatal care visits, implementation of SIAs in high-risk areas, and extension of outreach services to include vaccination of children, adolescent, and pregnant women with TTCV. India also promoted institutional deliveries through the provision of conditional cash transfers, communication with communities on clean cord care practices, and distribution of clean delivery kits to SBAs \[[@cit0044], [@cit0045]\].

As mentioned above, sensitive NT surveillance is a challenge for countries trying to achieve MNTE. Developing standardized NT surveillance guidelines with performance indicators similar to those used for acute flaccid paralysis (AFP for polio) and measles-rubella (MR) surveillance are needed to improve NT surveillance; such guidelines and indictors already exist for the Region of the Americas and could be adapted to other regions. Active surveillance for NT cases has been successfully integrated into existing active case-based surveillance activities for AFP and MR in many countries, resulting in more robust NT reporting. For example in Nepal, NT surveillance was integrated into the AFP surveillance system, which uses a network of surveillance medical officers reporting weekly from 413 sentinel surveillance sites (10% of government health facilities), and investigating suspected NT cases using a standard case-investigation form \[[@cit0046]\]. Since many neonatal deaths occur at home, it is important to supplement health facility-based surveillance with community based surveillance. In addition, sensitivity of NT surveillance may be improved through investigation of neonatal deaths reported through vital registration and reporting \[[@cit0031]\].

Sustaining elimination {#sec3.6}
----------------------

Because tetanus cannot be eradicated from the environment, countries need to have a plan for sustaining MNTE. Attention to MNT will likely decrease after elimination along with resources. However, efforts to ensure clean deliveries, maintain high immunization coverage of pregnant women, and strengthen NT surveillance should be continued through integration with routine programs. Countries with weak health systems that achieved elimination through SIAs need to have employed additional strategies for reaching women beyond routine services, which may include continued SIAs in high risk areas and outreach activities during child health days or antenatal care, to ensure population immunity does not lapse after MNTE validation \[[@cit0007]\].

Providing TTCV booster doses during the second year of life, childhood, and adolescence in the routine schedule will help ensure individuals of all ages and both sexes are adequately protected without relying on SIAs \[[@cit0003]\]. As school attendance has increased in the African region, school-based immunizations platforms are increasingly attractive platforms for administering booster doses during childhood and adolescence. In 2012, 24% of AFR countries reported providing vaccinations in school \[[@cit0047]\]. Opportunities to provide TTCV boosters increasingly exist as AFR countries, many with funding assistance from GAVI, the Vaccine Alliance, introduce vaccinations given beyond the first year of life, including a second dose of measles containing vaccine (MCV2) in the second year of life (2YL) and human papillomavirus vaccine in early adolescence \[[@cit0048]\]. As of September 2016, 25 (53%) AFR countries provided MCV2, most during the 2YL \[[@cit0016]\]. Additionally, booster doses would address tetanus immunity gaps in older children and adult men in the region \[[@cit0042], [@cit0049]\]. Attention was brought to the seriousness of this issue after cases of tetanus were reported following voluntary medical male circumcision in Eastern and Southern African countries \[[@cit0049], [@cit0050]\]. When countries develop plans to maintain MNTE, it is important to include booster doses for both sexes to improve equity, ensure long-term protection and decrease the burden of tetanus in all ages.

Most countries in the African meningitis belt have or will introduce the meningococcal serogroup A polysaccharide TT-conjugate vaccine (MenAfriVac) by conducting SIAs targeting persons aged 1--29 years, followed by introduction into the routine immunization schedule during the first or second year of life \[[@cit0016]\]. Results from a serosurvey conducted in Mali before and after the MenAfriVac campaign showed significant increases in tetanus immunity 2 years after the SIA \[[@cit0051]\]. A 25% reduction in NT cases was observed after MenAfriVac SIAs in 5 African countries, compared with before the SIA \[[@cit0052]\]. Therefore, MenAfriVac introduction in AFR countries in the meningitis belt could help boost tetanus immunity in those populations and support MNTE.

Effective NT surveillance, including sensitive and timely identification of NT cases, targeted implementation of control strategies, and effective monitoring and evaluation of the impact of these strategies, will be critical to sustaining MNTE. In addition to improving NT surveillance as mentioned above, annual reviews of data should be done to identify districts that could be at high-risk for MNT resurgence and need to implement additional control strategies to sustain MNTE \[[@cit0031]\]. In countries that have achieved MNTE, tetanus serosurveys of tetanus immunity in countries that have achieved MNTE can help supplement district level data reviews by identifying immunity gaps, which can provide evidence for the need for booster doses, including optimal schedules, and the need for targeted vaccination \[[@cit0031], [@cit0036]\].

Conclusion {#sec4}
==========

Though MNTE was not achieved in AFR by the target date of 2015, significant progress has been made in the region where 37 (79%) of 47 countries have achieved elimination as of November 2016. [Table 6](#t0006){ref-type="table"} summarizes the key findings of the MNTE strategies in the AFR region. In 2015, PAB and TT2+ coverage increased to 77% and 69% compared to 62% and 44% in 2000, respectively. Nevertheless, the region has 10 (56%) of the 18 countries worldwide that are yet to achieve MNTE. The majority of these countries are challenged with insecurity, weak health systems, competing priorities, and/or insufficient funding. In countries with insecurity, use of pre-filled injection devices, and integration of TTCV SIAs with polio and/or measles vaccination SIAs, or post-conflict campaigns, could help ensure tetanus protection among WRA in high-risk areas. To achieve and maintain MNTE, programs should use every available opportunity to provide TTCV to pregnant women, including in antenatal clinics, outreach, and during child health days. Providing the WHO-recommended TTCV booster doses to both sexes, e.g., in the 2YL, childhood (4-7 years), and adolescence (9--15 years), would help ensure women are protected before pregnancy and reduce the tetanus burden across the whole population. Case-based NT surveillance could be strengthened by development of standardized performance indicators and integration with active surveillance for AFP and MR. Countries that have achieved MNTE should develop plans to maintain elimination, including efforts to ensure high-quality NT surveillance and high tetanus immunity among WRA. Serosurveys may provide important information on tetanus population immunity for countries that have yet to achieve, as well as those that have already achieved MNTE.

###### 

Summary of Current Key Findings on the Status of Maternal and Neonatal Tetanus Elimination (MNTE) Strategies in the WHO African Region

  Programmatic areas                                                                                                                                                                             Key Findings
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tetanus Vaccination                                                                                                                                                                            Only 5/47 (11%) countries include the WHO-recommended 3 tetanus booster doses in their immunization schedules
  Regional average DTP3/Penta3 coverage has increased from 52% in 2000 to 76% in 2015                                                                                                            
  Among countries that have achieved MNTE, average TT2+ coverage among pregnant women and PAB have increased from 49% and 69% in 2000 to 84% and 86% in 2015, respectively                       
  Among countries that have not achieved MNTE average TT2+ coverage among pregnant women and PAB have increased from 19% and 54% in 2000 to 64% and 69% in 2015, respectively                    
  By the end of 2016, over 79 million WRA still need to be reached with at least 2 TTCVs                                                                                                         
  Clean Delivery and Cord Care                                                                                                                                                                   In 2013, the average percentage of births attended by SBAs was 54%
  Among countries that have achieved MNTE, 17/37 (46%) have \>70% SBA coverage                                                                                                                   
  Among countries that have not achieved MNTE, 1/10 (10%) have \>70% SBA coverage                                                                                                                
  Neonatal Tetanus Surveillance                                                                                                                                                                  NT surveillance is weak in most countries leading to underreporting of cases, with the efficiency of notification for NT cases globally estimated at less than 11%
  NT surveillance could be strengthened with case investigations, standardized performance indicators, and better integration with active surveillance for measles and acute flaccid paralysis   
  Serosurveys can help monitor progress towards achieving or maintaining MNTE                                                                                                                    

WHO=World Health Organization; MNTE= Maternal and Neonatal Tetanus Elimination; WRA = Women of Reproductive Age; TTCV = Tetanus Toxoid Containing Vaccines; SAB = Skilled Birth Attendants; NT= Neonatal Tetanus

Sources and calculations for averages are described in the methods section

What is known about this topic {#sec4.1}
------------------------------

-   Maternal and neonatal tetanus is preventable through appropriate vaccination of pregnant women and implementation of clean delivery and umbilical cord practices;

-   Because of efforts towards maternal and neonatal tetanus elimination (MNTE), neonatal mortality from tetanus has declined an estimated 94% between 1988 and 2013;

-   Worldwide, 41 (69%) of 59 priority countries have achieved MNTE, with 18 countries yet to achieve elimination, including 10 countries in the African region.

What this study adds {#sec4.2}
--------------------

-   As of November 2016, over 79 millions women of reproductive age in countries in the African region (AFR) have been reached with at least 2 doses of tetanus-toxoid containing vaccines through supplemental immunization activities;

-   Challenges to achieving MNTE in AFR countries include insecurity, weak health systems, competing priorities, and insufficient funding, but 7 of 10 AFR countries are on track to achieve MNTE by 2018;

-   Only 5 (11%) AFR countries currently provide the 3 WHO-recommended tetanus booster doses during childhood, adolescence, and early adulthood to provide long-term protection against tetanus and assist with sustaining MNTE.
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